Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAG | P20916 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GJB2 | P29033 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16489961 | 0.96 | MAG (0.35) | LMNAKMT2AMAGSLC6A2L3MBTL1 | |
| SCHEMBL16489956 | 0.96 | LMNA (0.36) | LMNAKMT2AL3MBTL1POLBTP53 | |
| SCHEMBL16489972 | 0.91 | LMNA (0.37) | LMNAKMT2AMAGL3MBTL1POLB | |
| SCHEMBL16489970 | 0.90 | LMNA (0.38) | LMNAKMT2AMAGSLC6A2L3MBTL1 | |
| SCHEMBL16489967 | 0.89 | LMNA (0.37) | LMNAKMT2AMAGL3MBTL1POLB | |
| SCHEMBL15975409 | 0.86 | TP53 (0.37) | LMNAKMT2AMAGL3MBTL1POLB | |
| SCHEMBL16489966 | 0.86 | L3MBTL1 (0.36) | LMNAKMT2AMAGSLC6A2L3MBTL1 | |
| SCHEMBL15975394 | 0.85 | PTPN1 (0.38) | LMNAKMT2AMAGL3MBTL1POLB | |
| SCHEMBL13129950 | 0.85 | PTPN1 (0.38) | LMNAKMT2AMAGL3MBTL1POLB | |
| SCHEMBL16489958 | 0.85 | LGALS8 (0.40) | LMNAKMT2AMAGSLC6A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150050282-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3a AND X | INSTITUT PASTEUR (FR) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150050282-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3a AND X | ST3GAL3, SI, STT3A | LMNA 3255/4885KMT2A 3430/4885MAG 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.